Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT

CONTEXT: Vasomotor symptoms (VMS) are common, bothersome, and can persist for years before and after menopause. OBJECTIVE: We aimed to assess efficacy/safety of fezolinetant for treatment of moderate to severe VMS associated with menopause. METHODS: In this double-blind, placebo-controlled, 12-week...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Kimball A, Martin, Nancy, Nappi, Rossella E, Neal-Perry, Genevieve, Shapiro, Marla, Stute, Petra, Thurston, Rebecca C, Wolfman, Wendy, English, Marci, Franklin, Catherine, Lee, Misun, Santoro, Nanette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348473/
https://www.ncbi.nlm.nih.gov/pubmed/36734148
http://dx.doi.org/10.1210/clinem/dgad058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348473/
https://www.ncbi.nlm.nih.gov/pubmed/36734148
http://dx.doi.org/10.1210/clinem/dgad058

Ejemplares similares